ARDELYX, INC. (NASDAQ:ARDX) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure. |
On June21, 2017, Ardelyx, Inc. (the Company) updated its
corporate presentation (the Corporate Presentation) in connection
with upcoming investor conferences. A copy of the Corporate
Presentation is furnished as Exhibit 99.1 to this Current Report
on Form 8-K, and incorporated by reference herein.
The information furnished under this Item7.01 (including Exhibit
99.1) shall not be considered filed under the Securities Exchange
Act of 1934, as amended, nor shall it be incorporated into any
future filing under the Securities Act of 1933, as amended, or
under the Securities Exchange Act of 1934, as amended, unless the
Company expressly sets forth in such future filing that such
information is to be considered filed or incorporated by
reference therein.
Item9.01 |
Financial Statements and Exhibits. |
(d) |
Exhibits. |
|
|
|
|
| 99.1 | Corporate presentation of Ardelyx, Inc. |
ARDELYX, INC. ExhibitEX-99.1 2 d382558dex991.htm EX-99.1 EX-99.1 BREAKTHROUGH SCIENCE FOR BETTER HEALTH NASDAQ: ARDX Exhibit 99.1 FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx,…To view the full exhibit click here About ARDELYX, INC. (NASDAQ:ARDX)
Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment. It has discovered and designed its lead product candidate, tenapanor, which is a minimally systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduce sodium and phosphorus uptake from the gut. It is evaluating tenapanor in over two pivotal Phase III clinical studies in patients with constipation-predominant irritable bowel syndrome (IBS-C). It is developing RDX022 for the treatment of hyperkalemia. RDX022 is its oral, non-absorbed potassium-binder. Its development programs also include RDX009 Program, RDX013 Program and RDX011 Program.
